# Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic Dermatitis

> **NCT04504279** · PHASE2 · COMPLETED · sponsor: **Forte Biosciences, Inc.** · enrollment: 154 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **BIOLOGICAL:** FB-401
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT04504279
- **Lead sponsor:** Forte Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-13
- **Primary completion:** 2021-07-14
- **Final completion:** 2021-08-19
- **Target enrollment:** 154 (ACTUAL)
- **Last updated:** 2021-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04504279

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04504279, "Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic Dermatitis". Retrieved via AI Analytics 2026-09-15 from https://api.ai-analytics.org/clinical/NCT04504279. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*